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A B S T R A C T
Gastro-retentive drug delivery system (GRDDS) has gained immense popularity in the field
of oral drug delivery recently. It is a widely employed approach to retain the dosage form
in the stomach for an extended period of time and release the drug slowly that can address
many challenges associated with conventional oral delivery, including poor bioavailability.
Different innovative approaches like magnetic field assisted gastro-retention, plug type swell-
ing system, muco-adhesion technique, floating system with or without effervescence are
being applied to fabricate GRDDS. Apart from in vitro characterization, successful GRDDS
development demands well designed in vivo study to establish enhanced gastro-retention
and prolonged drug release. Gama scintigraphy and MRI are popular techniques to evalu-
ate in vivo gastric residence time. However, checking of their overall in-vivo efficacy still remains
a major challenge for this kind of dosage form, especially in small animals like mice or rat.
Reported in vivo studies with beagle dogs, rabbits, and human subjects are only a handful
in spite of a large number of encouraging in vitro results. In spite of the many advantages,
high subject variations in gastrointestinal physiological condition, effect of food, and vari-
able rate of gastric emptying time are the challenges that limit the number of available GRDDS
in the market. This review article highlights the in vivo works of GRDDS carried out in the
recent past, including their limitations and challenges that need to be overcome in the near
future.
© 2016 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Oral formulations have earned a significant place among the
various dosage forms developed so far for human adminis-
tration. In most of the cases, the conventional oral delivery
systems show limited bioavailability because of fast gastric-
emptying time among many other reasons involved [1,2].
However, the recent technological development has resulted
to many novel pharmaceutical products, mainly the con-
trolled release drug delivery systems to overcome this problem.
Gastro-retentive drug delivery system (GRDDS) is one such
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example where the attribute like gastric retention time coupled
with the drug release for extended time has significantly im-
proved patient compliance. Some inherent limitations of the
conventional oral drug delivery systems have ignited the in-
terest to this new delivery system. Fast gastric emptying
associated with conventional oral medications leads to a
bioavailability issue for many drug molecules (e.g. pranlukast
hydrate,metformin HCl, baclofen, etc.), of which the main prin-
cipal site of absorption is the stomach or the proximal part of
the small intestine, or have the absorption issue in the distal
part of the intestine [3–5]. Solubility can also be improved by
prolonging the gastric retention of drugs that are less soluble
in an elevated pH environment of the intestine [2]. There are
many drugs (e.g. captopril, metronidazole, ranitidine HCl, etc.)
that are prone to degradation in the colonic area [2,6].To attain
required therapeutic activity, recurrent dosing is needed for the
drugs with short half-lives as they have the tendency of getting
eliminated quickly from the systemic circulation. However, an
oral sustained-controlled release formulation with addi-
tional gastric retention property can avoid these limitations
by releasing the drug slowly in the stomach along with main-
taining an effective drug concentration in the systemic
circulation for an extended period of time [7]. Apart from the
systemic action, GRDDS has proved to be effective locally to
treat gastric and duodenal ulcers, including esophagitis, by
eradicating the deeply buried Helicobacter pylori from the sub-
mucosal tissue of the stomach [2,5,8–10].The history of GRDDS
formulations dates back to almost three decades [11].The basic
fabrication techniques, including their in vitro characteriza-
tions, are also well established. Even in recent times, quite a
few reviews have been published on GRDDS [5,12–18]. These
reviews are more focused on the formulation aspects or in vitro
characterization studies done by various researchers or overall
GRDDS. The industrial aspects covering physicochemical,
biopharmaceutical and regulatory considerations of GRDDS have
been reviewed by Pawar et al. [19]. Still, the number of mar-
keted gastro-retentive formulations is not significant. So, it is
very important to look through the in vivo studies done with
GRDDS in order to find out the pharmacokinetic perfor-
mances of the developed systems considering their significant
roles in successful commercialization of any dosage form. As
per our literature search, there is no review available to date
focusing on in vivo performances of GRDDS, especially on recent
works. In this context, the aim of this review is to summarize
the in vivo studies of GRDDS in terms of pharmacokinetic pa-
rameters as well as gastro-retention times and the inherent
challenges or constraints for in vivo evaluations recorded by
various researchers.
2. Stomach physiology
Success of GRDDS relies on the understanding of stomach
physiology and related gastric emptying process. Structurally
the human stomach is composed of three anatomical regions:
fundus, body and antrum (pylorus), as depicted in Fig. 1. After
a meal, the average volume of a stomach is about 1.5 l, which
varies from 250 to 500 ml during the inter-digestive phases [18].
The part made of the fundus and the body acts as a reservoir
of any undigested material, while the antrum performs as the
principal site for the mixing action. Being the lower part, the
antrum works as a pump for gastric emptying by a propel-
ling action. Pylorus acts to separate the stomach from the
duodenum and plays a major role in gastric residence time of
the ingested materials. However, the pattern of the gastric mo-
tility is different for the fasting and fed state [20]. The gastric
motility pattern is systematized in cycles of activity as well as
quiescence.The duration of each cycle is 90–120 min and it con-
tains four phases, as mentioned in Table 1 [21]. The motility
pattern of the stomach is usually called migrating motor
complex (MMC) [17].
3. Approaches to fabricate gastro-retentive
systems
Different approaches have been adopted by researchers to
enhance gastric residence time with the prolonged drug release.
The concept of high density formulation is one such ap-
proach (Fig. 2). The developed dosage form was made heavy
(density: 2.5 to 3.0 g/ml) to withstand in vivo peristaltic move-
ment and remained intact in spite of the GIT disturbance.
Accordingly, the GI transit time was expected to prolong for
Fig. 1 – Diagram of human stomach.
Table 1 – Four phases of migrating motor complex
(MMC).a
Phase Description Duration
(min)
Phase I
(basal phase)
Idle state without any
contraction
30 to 60
Phase II
(pre-burst phase)
Intermittent contraction 20 to 40
Phase III
(burst phase)
The regular contraction
at the maximal frequency
causes the good material
to migrate distally.
10 to 20
Phase IV Transition period between
phase III and phase I
0 to 5
a From Talukder and Fassihi [21].
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an average of 5.8 h to 25 h [7,22]. Barium sulfate, iron powder,
titanium oxide, and zinc oxide were incorporated in the for-
mulation to increase the density of the dosage form. Increased
dose size required to achieve that high density was one of the
major drawbacks of this kind of system, as reported by Chawla
et al. [23]. Another novel idea was postulated to retain the
dosage form within the stomach by the application of a mag-
netic field.The dosage form would contain magnetically active
elements. One external magnet was required to position on
the abdomen over the location of the stomach to retain the
administered drug in place (Fig. 3).Though innovative in design,
lack of patient compliance was one of the major setbacks for
in vivo design of this delivery system [24].
With the introduction of swelling and expanding system
(Fig. 4), GRDDS managed to achieve significant success both
in vitro and in vivo in order to retain the dosage form in the
stomach [25,26]. Bolton and Desai [27] reported one such system
that was designed to increase in size bigger than the diam-
eter of pyloric sphincter and remain logged there (Fig. 4).
Alternatively, the system was named as ‘plug type systems’
due to their pyloric sphincter blocking attribute. Once the
polymer came in contact with the gastric fluid, it absorbed water
and swelled [18,28–30]. The selection of a suitable polymer (or
combination of polymers) with an appropriate molecular
weight/viscosity grade and swelling properties enabled the
dosage form to attain sustained-release characteristic. Further
advancement of such kind of dosage form has taken place with
the introduction of novel polymers with super-porous nature,
causing them to swell to an equilibrium size within a minute.
This characteristic rapid swelling property (swelling ratio is 1:100
or more) of the polymer with an average pore size of more than
100 μm occurs due to capillary wetting through several inter-
related open pores when the dosage form comes in contact
with GI fluid [31].
Another type of GRDDS has been designed utilizing buoy-
ancy (floating) property of any dosage form experienced in GI
fluid [32].The bulk density of the dosage form attains less than
the density of gastric fluid (1.004 to 1.010 g/ml) after a certain
lag time. This lag time depends on the rate of swelling of the
polymer used in the formulation, which again depends on the
type, viscosity grade, presence of wicking agent or swelling en-
hancers, etc. [33–35]. The said parameters of the formulation
also determine the duration of floating as well as in vitro drug
release rate.The efficacy of the floating behavior also depends
on the physiological conditions of the patients, like fed-state
or fasting state, amount of gastric fluid, etc. [1]. After the re-
quired drug release, the used dosage form is emptied out from
the stomach [36]. One additional attribute such as efferves-
cence was incorporated within this swelling-based floating
delivery system to improve the floating behavior (floating lag
time as well as floating duration), as shown in Fig. 5 [37–41].
Various effervescent components (e.g. sodium bicarbonate,
Fig. 2 – Gastro-retentive drug delivery system based on
high density.
Fig. 3 – Gastro-retentive drug delivery system based on
application of magnetic force.
Fig. 4 – Gastro-retentive drug delivery system based on
polymer swelling.
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tartaric acid and citric acid) were mixed within the dosage form.
When these components come in contact with the gastric con-
tents, carbon dioxide (CO2) is liberated as a result of a chemical
reaction and it becomes trapped within the gellified hydro-
colloid system. These combinations of effervescence and
swelling help the dosage form achieve effective density less
than the gastric fluid and result an upward motion onto a
dosage form which maintains the buoyancy for a prolonged
period of time [37]. In addition to the single unit systems, the
bi-layers and tri-layers design of this combination approach
has also been considered to incorporate two different drugs
with different release profiles [37]. One of the drugs and ex-
cipients is individually formulated as sustained release layer
containing the gas generating unit, whereas the outer layer in-
cludes the second drug for immediate release profile [42]. Bio-
adhesive or muco-adhesive drug delivery systems were also
tried as gastro-retentive systems.The dosage form was made
to be attached inside the lumen of the stomach wall and survive
the gastrointestinal motility for a longer period (Fig. 6). It was
also beneficial as a site specific design to promote local drug
absorption in an infected area of the stomach. Muco-adhesive
excipients like polycarbophil, lectins, carbopol, chitosan, car-
boxymethylcellulose (CMC), pectin and gliadin were reported
as formulation compositions for this kind of design [43–45].The
combination of macho-adhesion and floating or swelling
mechanism is being adopted as another novel approach for im-
proved gastro-retention attributes [9,46,47].
In-situ gelling technique (also known as raft forming system)
in combination with carbon dioxide bubble entrapment was
also reported as another patient compliance design for gastro-
retention. This type of delivery system, initially as a solution
form, contains sodium alginate as in situ gel forming polymer
along with carbonates or bicarbonates as effervescent agents.
When they come in contact with the gastric fluid, they swell
and generate a viscous cohesive gel that contains entrapped
carbon dioxide bubbles, causing the drug delivery systems to
float. For gastroesophageal reflux treatment, raft forming
systems are frequently used because of their tendency to
produce a layer on the upper part of the gastric fluid [48,49].
4. In vitro assessment of GRDDS
In vitro evaluations of GRDDS are prerequisite to ensure the in
vivo performance with respect to floating lag time and float-
ing duration, as well as selection of right formulation
composition. In case of tablet dosage form, the routine evalu-
ation tests include general tabletting parameters like hardness,
friability, general appearance, drug content, uniformity of
content,weight variation, and in vitro drug release [37]. For evalu-
ation of floating behavior like floating lag time and the duration
of floating for any GRDDS, deionized water and simulated gastric
fluid have been used in the literature [50]. These two media
are used to observe possible differences in buoyancy capabili-
ties of the dosage forms. Additionally, swelling property and
the rate of swelling of the polymeric dosage forms placed in
a dissolution medium (0.1N HCl) are tested for at least 8 h to
ensure drug release and floating mechanism. This is done by
measuring the size of the swollen tablet or the weight gain after
collecting them at the end of the study [46]. For in vitro drug
release test, simulated gastric fluid is used as the test medium.
Samples are withdrawn from the dissolution baskets with a
predetermined time interval and are diluted appropriately to
be analyzed for the drug content [51]. Microscopic observa-
tion, preferably scanning electron microscopy (SEM), is used
at different magnification powers for visualization of the surface
morphology of the dosage form. For the gastro-retentive beads
andmicrospheres, some other additional tests like drug loading,
particle size analysis and drug entrapment efficiency are per-
formed to optimize formulation composition and related
processing parameters [52,53]. Spectrophotometer, optical mi-
croscope and particle size analyzer are routinely used in these
types of in vitro evaluation tests.
Fig. 5 – Gastro-retentive drug delivery system based on
combination of polymer swelling and effervescence.
Fig. 6 – Gastro-retentive drug delivery system based on
muco-adhesion.
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5. In vivo gastric retention as a surrogate of
pharmacokinetic study
A well-designed in vivo study in appropriate animal model or
healthy human subjects is required to prove the in vivo effi-
cacy of anyGRDDS.However,handling smaller animals likemice,
rats, guinea pigs or rabbits for checking the gastric retention
along with bioavailability study is difficult, especially for a big
size tablet dosage form, as reported byTurner et al. [54].That’s
whymost of the literatures on formulation of GRDDShad shown
the proof of in vivo gastric retention in relatively bigger sized
animals like dog or human subjects, together with important
in vitro characterization studies such as dissolution study, es-
timation of floating lag time andfloating duration.The extended
in vivo gastric retention was hypothesized that the GRDDSwas
supposed to give improved therapeutic efficacy as compared
to the conventional dosage form. Many sophisticated visual-
ization techniquesarehelpful in this regard.Gammascintigraphy
is one such popular and elegant technique to provide appro-
priate assessment of gastro-retentivity in humans. A small
amount of radioisotopewith short half-life is incorporatedwithin
the dosage form.The formulation is exposed to a neutron source
that can cause it to release the characteristic gamma rays to
be captured as an image after processing by a computer [55].
Badve et al. [56] formulated hollow calcium pectinate beads of
diclofenac sodium for its chronopharmacological action. The
floating beads were structurally hollow spheres with a bulk
density of less than 1 g/ml and 34% porosity. An in vivo study
was done on rabbits by gamma scintigraphy, which showed
gastro-retention of beads up to 5 h.There aremany other recent
reports of success in vivo gastric retention of floating tablets
and microspheres containing versatile drug molecules like
ascaridole, calcium-disodiumedentate, and repaglinide [57–59].
Magnetic Resonance Imaging (MRI) is another technique to prove
in vivo gastro-retention of a GRDDS.This is comparatively a safe
technique that uses magnetic fields and radio waves to view
the complete anatomical structure along with the location of
the ingested dosage form. The compounds with super para-
magnetic properties (e.g. ferrous oxide) are incorporated for the
visualization purpose [51]. Steingoetter et al. [60] used this tech-
nique to report the in vivo gastric retentionof gadoliniumchelates
(Gd-DOTA) floating tablet containing Fe3O4 as a super-
paramagnetic agent and succeeded in analyzing intra-gastric
tablet position and residence time in human volunteers. Ra-
diology or X-ray is another alternative techniquewhere a radio-
opaquematerial is incorporatedwith theGRDDS.This technique
has been reported in the evaluation of gastro-retentivity, the
disintegration rate of dosage forms and their esophageal transit
[61]. However, the safety issue is associated with this tech-
nique as repetitive exposure to X-ray may incur health hazard
[62]. In spite of that, the technique has the advantage of using
it successfully in human volunteers, dogs, and rabbits [63–67].
To diagnose andmonitor the GIT, gastroscopy is another com-
monly used technique. Fiber optics or video system is used to
locate the dosage form by this technique. As this procedure is
less convenient, sometimes it is applied with minor anesthe-
sia in human to assess gastric retention of any dosage form
[68]. But in case of dogs, complete anesthesia is required, as
reported by Dhiman et al. [51].
6. In vivo success of GRDDS in the
background of pharmacokinetic attributes
Based on a huge volume of literatures, it is quite established
that oral gastro-retentive drug delivery system has been widely
explored within the last three decades of research in drug de-
livery. However, only a handful of them have been evidenced
with in vivo proofs. The following sections contain a glimpse
of them arranged chronologically for animal and human sub-
jects separately:
6.1. Animal study
Klausner et al. [18] developed a novel controlled release GRDDS
of Levodopa by using unfolding polymeric membranes with ex-
tended dimensions and high rigidity. In vivo study was done
with the beagle dogs pretreated with carbidopa. The devel-
oped formulation was administered and the location of the
dosage form in the gastrointestinal tract was determined by
X-ray. Also, serial blood samples were collected and exam-
ined for the active drug. It was found that the optimized
controlled release GRDDS of Levodopa was able to maintain
the therapeutic concentrations of Levodopa (>500 ng/ml) over
9 h. The mean absorption time was considerably prolonged
compared to non-GR controlled release-particles and oral
solution.
Jain et al. [57] formulated floating microsphere of repaglinide
(hypoglycemic agent) where calcium silicate was used as porous
carrier and Eudragit as polymer. Sprague Dawley male rats were
subjected to the organ distribution study and suspension of
99mTc-labeled floating microspheres were administered to
albino rabbits orally with water.After the gastric residence time
of 6 h as confirmed by gamma scintigraphy, the rats were sac-
rificed and organs were isolated (stomach and intestinal region).
Organ distribution of the test compound was found to be
uniform and the relative bioavailability was 3.17 times com-
pared to marketed tablets.
In vivo anti-tumor study was carried out by Shishu and
Aggarwal [69] to check the therapeutic efficacy of floating
calcium alginate beads of 5-flurouracil. It was found that the
multiple unit floating system was able to reduce gastric tumor
incidence by 74% in mice where the reduction of this inci-
dence was found to be only 25% in the case of a conventional
tablet dosage form.
Pande et al. [70] prepared cefpodoxime proxetil microspheres
as GRDDS.The solvent evaporation technique was used for the
development of the drug loaded microspheres where ethyl cel-
lulose and HPMC were used as the release retarded materials.
Two groups of male albino rats were subjected to oral inges-
tion of the cefpodoxime proxetil microspheres and cefpodoxime
proxetil suspension at a dose of 10 mg/kg. Blood samples were
collected at a pre-determined time intervals from retro-
orbital region and centrifuged for separating plasma samples,
which were finally analyzed by HPTLC. This study resulted in
an increase of the relative bioavailability of the drug formu-
lated into the microspheres which was 1.5 times more
compared to the suspension.
Guan et al. [71] confirmed the efficacy of a gastro-retentive
floating osmotic capsule containing famotidine as compared
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to its marketed formulation.The developed capsules were based
on novel asymmetric membrane technology where the mem-
brane was composed of glycerin and diethyl phthalate.
Polyethylene oxideWSR N-80 (molecular weight 200,000) was
used to prepare the sustained release floating granules en-
capsulated within the capsule shells.The optimized formulation
provided in vitro zero-order drug release profile and floating time
both for 12 h. Six healthy male beagle dogs were adminis-
tered the optimized 40 mg floating capsules (Test) and
famotidine 20 mg commercial tablets (two tablets per admin-
istration as Reference) in a well-designed in vivo study and blood
samples were withdrawn for 36 h. Peak plasma concentra-
tion (Cmax) for the Reference formulation was found to be
0.334 μg/ml as compared to 0.187 μg/ml for the Test formula-
tion capsule. Similarly, the time to reach peak plasma
concentration (Tmax) for the Reference tablet was 2.083 h as
against 4 h for the Test capsule. Elimination half-life (t1/2) was
found to be approximately double for floating capsule (23.634 h)
as compared to that of commercial tablet (13.178 h). As ex-
pected, the area under the curve (AUC0−∞) for the Reference tablet
was found to be 31.411 μg/ml, whereas for the Test capsules
it was 50.4 μg/ml. Accordingly, the relative bioavailability of de-
veloped capsule was about 1.605 times higher than the
commercial formulation. This in vivo study clearly proved the
advantage of gastro-retentive formulation over conventional
one.
Khan and Dehghan [72] reported enhanced bioavailability
of atorvastatin calcium, a hypolipidemic drug, administered
in albino rabbits as floating tablets.With an in vitro floating lag
time of 56 ± 4.16 s and floating duration of 6 h, the tablets could
enhance the bioavailability 1.6 times compared with that of
the conventional tablets.
The stomach is the major absorption site for cephalexin and
gastro-retentive formulation could achieve its enhanced
bioavailability as confirmed byYin et al. [73]. Cephalexin loaded
gastro-floating tablets were prepared by hydroxypropyl meth-
ylcellulose (HPMC K100M) as a matrix and sodium bicarbonate
as a gas-forming agent. The developed tablets had a floating
lag time below 15 s and floating duration of more than 12 h
with a satisfactory in vitro sustained-release profile for 12 h.
An in vivo pharmacokinetic study was conducted in fed and
fasted beagle dogs comparing with conventional capsules and
sustained release tablets. Cephalexin floating tablets re-
sulted in a relative bioavailability of 99.4% with an extended
drug release profile, while the reference formulations gave a
relative bioavailability of only 39.3%. However, the study had
shown a significant effect on the pharmacokinetics of
sustained-release tablets.
Thakar et al. [4] reported an in vivo study on rabbits for the
floating tablets containing baclofen. Composed of PolyoxWSR
303 and HPMC K4M as swelling polymers and sodium bicar-
bonate as gas generating agent, the tablets showed favorable
gastro-retentive properties like a floating lag time of 4 to 5 s
and floating duration of more than 12 h. In line with the in vitro
properties, the optimized floating dosage form provided pro-
longed gastric residence time and showed a 2.34 times increase
in bioavailability as compared to the commercial formulation.
Combination of floating and bioadhesion was found to
provide improved in vivo efficacy of famotidine mini-tablets fab-
ricated by Zhu et al. [74] with HPMC K4M as release retarding
and swelling polymer together with carbopol 971P (bioadhesive
materials) and sodium bicarbonate (gas-forming agent).Tested
in rat models, the mini-tablets could result in a 1.62-fold en-
hancement in bioavailability.
Qi et al. [75] reported in vivo success of the compression
coated floating tablet of ofloxacin. The tablets were prepared
by hydroxypropyl cellulose as compression coating agent,
sodium alginate as a drug release modifier, and sodium bicar-
bonate as an effervescent agent. In vitro attributes of the tablets
like a floating lag time of 30 s and floating duration of 12 h were
well correlated with its relative bioavailability of 172% against
the market formulation studied in New Zealand rabbits.
The combination of effervescence and swelling floating
mechanism as a mean of superior gastro-retentivity and in vivo
efficacy was proven by Kadivar et al. [67] for imatinib mesylate
sustained release tablet prepared with HPMC K4M, sodium al-
ginate and carbomer 934P. Studied in New Zealand rabbits, the
gastro-retentive tablets could increase the bioavailability around
1.5 times compared to the conventional tablets (Gleevec).
6.2. Human study
Chen et al. [76] developed a gastro-retentive tablets based on
swelling/effervescence mechanism with a combination of
hydroxyethyl cellulose, sodium carboxymethyl cellulose, and
sodium bicarbonate for administering antihypertensive drug
losartan.Tablets were found to remain floating in vitro for more
than 16 h with a swelling to 2 cm in diameter within 3 h. Ad-
ditionally, the tablets showed pH-dependent drug release with
an extension for 24 h. When tested in healthy human volun-
teers, the optimized tablets achieved an enhanced bioavailability
of approximately 164% relative to the immediate release market
formulation named Cozaar®. As expected, the gastro-retentive
floating tablets produced favorable pharmacokinetic param-
eters: maximum residence time (MRT) and Tmax values were
greater and Cmax values were lower as compared to the com-
mercial formulation.
Bomma and Veerabrahma [66] established efficacy of anti-
biotic treatment with gastro-retentive tablets of cefuroxime
axetil over conventional tablets, Zocef®. Developed and opti-
mized tablets were based on a combination of swelling (HPMC
and PolyoxWSR 303) and effervescence (citric acid, calcium car-
bonate) mechanism. In line with in vitro floating duration of
more than 12 h with a floating lag time of less than 30 s, the
optimized tablets could be retained 225 ± 30 min in human sub-
jects as confirmed by in vivo radiographic studies. The same
tablets were tested on eight healthy human volunteers. The
developed floating tablets showed superior bioavailability than
Zocef tablet. Based on in vivo performance, a significant dif-
ference was observed in Cmax, Tmax, t1/2, AUC0–∞, and mean
residence time between test and reference (P < 0.05). As com-
pared to the reference tablets, the floating tablets of cefuroxime
axetil resulted in an increase of 1.61-fold relative bioavailability.
In vivo efficacy of GRDDS containing a high load of nico-
tinamide (600 mg) as an active drug was patented by Meijerink
et al. [77]. Hypromellose was used as a swelling agent in that
formulation. Eight healthy adult volunteers were used to explore
their pharmacokinetic profiles. Blood samples as well as urine
were collected at a pre-determined time intervals. The devel-
oped dosage form was capable of maintaining an increased
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nicotinamide plasma levels in vivo for a period of at least 8 h
after ingestion by the volunteers.
Ranade et al. [78] studied ellagic acid and aloe vera gel
powder as a bilayer floating tablet prepared with HPMC K15M
and sodium bicarbonate to treat stomach ulcer. The research-
ers reported 75% ulcer inhibition in comparison to 57% ulcer
inhibition with ellagic acid alone. This efficacy was resulted
from the tablets that showed in vitro floating duration of only
4 h with a cumulative 92% drug release.
In another study, efficacy of gastro-retentive emulsion gel
calcium pectinate beads contacting cinnarizine prepared by the
ionotropic gelation method was established by Abouelatta et al.
[79]. The researchers reported improved in vivo efficacy with
a mean AUC0–24 and AUC0–∞ enhancement of 1.79 and 3.80 times,
respectively, compared to a conventional tablet in healthy
human volunteers. Interestingly, the beads composed of pectin
(base), glyceryl monooleate and labrafac lipophileWL 1349 (oil
phase) had instant in vitro floating capacity.
Although many GRDDS with various novel fabrication
options have been reported for their in vitro success, their com-
mercialization success is not significant. A glimpse of a few
new candidates together with the old ones is summarized in
Table 2 [5,19,80].
7. Challenges ahead with GRDDS
The retention time of the dosage forms in the GIT is one of the
determinants of the bioavailability of oral drug delivery systems.
In case of GRDDS, it is rather specific to the stomach only.There-
fore, for developing a GRDDS, the main challenge is retaining
the delivery system in the stomach or the upper part of the
small intestine for a long time until all the drugs have been
released at a predetermined rate [74]. The process of gastric
emptying time is highly variable. Among many other factors,
it mainly depends on the dosage form as well as fed or fasted
state of the stomach.The gastric retention time is extended in
the fed state,whereas shortened by the fasting state [81]. Other
physiological barriers and factors like the type of food, caloric
content, gender and age play significant roles in the variation
of gastric emptying time [82]. Because of high caloric content,
high fat meal strongly prolongs the process of gastric empty-
ing. Indigestible polymers or fatty acid salts also modify the
motility pattern of the stomach under fed state and help in
reducing gastric emptying rate [1]. Additionally, patients have
variable GRT depending on gender and age, as reported by
Mojaverian et al. [83]. The pylorus limitation plays an impor-
tant role in gastric retention of any GRDDS.The pylorus size is
about 2 to 3 mmduring the digestion and the diameter becomes
12.8 ± 7.0 mm during the inter-digestive phase. Thus, all par-
ticles must have a diameter lower than 5 mm so that they can
pass through the pylorus into the duodenum [84].Another factor
to consider here is the variation in pylorus size and its peri-
staltic movement of the animal (e.g. dog, rabbit model) from
that of the human [85]. So, in vivo efficacy results need to be
concluded carefully. Size and shape of the dosage form, indi-
vidual’s disease state, and body mass index are some other
factors onwhich gastric residence time is dependent and related
to the efficacy of the dosage form [84]. However, it has been
reported that sometimes multiple-unit GRDDS shows an im-
proved and predictable drug release compared to a single-
unit GRDDS.Due to a combination of the lag time and the gastric
emptying process, a single unit gastro-retentive dosage form
(GRDF)may ultimately exit the stomach before the dosage form
becomes functional [5]. Hence, to develop an optimumGRDDS,
the main challenges are to overcome the problems associated
with the gastric emptying rate of the stomach together with
maintaining an appropriate drug release rate for an extended
period of time before it gets metabolized in the system [86].
Table 2 – List of commercialized gastro-retentive drug delivery system (GRDDS).a
Product Drug Company Technology
Liquid Gaviscon® Alginic acid and sodium bicarbonate Reckitt Benckiser Healthcare, UK Effervescent floating
Cipro XR® Ciprofloxacin HCl and betaine Bayer, USA Erodible matrix-based system
Prazopress XL® Prazosin hydrochloride Sun Pharma, Japan Effervescent and swelling-based floating system
Conviron® Ferrous sulfate Ranbaxy, India Colloidal gel forming floating system
Cefaclor LP® Cefaclor Galenix, France Floating system
Tramadol LP® Tramadol Galenix, France Floating system
Baclofen GRS® Baclofen Sun Pharma, India Coated multi-layer floating and swelling system
Gabapentin GR® Gabapentin Depomed, Inc., USA Polymer-based swelling technology
Proquin XR® Ciprofloxacin Depomed Inc., USA Polymer-based swelling technology
Glumetza® Metformin HCl Depomed Inc., USA Polymer-based swelling technology
Madopar® Levodopa and benserazide Roche, UK Floating capsule
Valrelease® Diazepam Roche, UK Floating capsule
Topalkan® Aluminum and magnesium Pierre Fabre Medicament, France Floating liquid alginate
Xifaxan® Rifaximin Lupin, India Bioadhesive tablets
Coreg CR® Carvedilol GlaxoSmithKline Gastro-retention with osmotic system
Inon Ace® Simethicone Sato Pharma, Japan Foam-based floating system
Cytotec® Misoprostol Pharmacia/Pfizer Inc., USA Bilayer floating capsules
Cifran OD® Ciprofloxacin HCl Ranbaxy, India Floating tablets
Oflin OD® Ofloxacin Ranbaxy, India Gas generating floating tablets
a Prinderre et al. [5], Pawar et al. [19], and Kotreka and Adeyeye [80].
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8. Conclusions
According to the review of different published literature and
detailed investigations on commercial products, it can be con-
cluded that no single gastro-retentive system could be marked
as the best suited for any drug candidate. However, several ad-
vantages of GRDDS for patients have been evidenced in the
majority of them. Individual drug candidate or a combina-
tion of the drugs needs to be assessed case by case regarding
the necessary dose and the ease of manufacturing process.
Polymer selection remains a critical factor for the formula-
tions that contain high dose.This selection is essential for the
compressibility needed to exploit the high doses of the APIs.
However, the criteria of ideal polymer should be based on its
amount in the dosage form; a minimum quantity that pro-
vides a substantial gastric retention should be preferred [5].
Although several approaches like floating, bio-adhesion, ef-
fervescence, sinking,magnetic, swelling, etc. have been proposed
over the years, reports on their in vivo success have not been
captured significantly. Formulation wise, the major trend has
been shifted toward the use of swelling polymer matrix to-
gether with effervescence in the design of floating delivery
systems. Commercially it is emerging slowly as an important
novel drug delivery due to many inherent challenges associ-
ated with it in spite of the numerous potential benefits offered
by this delivery system. In terms of delivering drugs to the sys-
temic circulation along with enhanced effectiveness, it is
expected that GRDDS will become more popular in the near
future. However, it is necessary to establish their efficacy by
properly designed in vivo studies for a specific drug because
of the complexity in pharmacokinetic and pharmacody-
namic parameters.
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